Investigational therapies

Arcutis Biotherapeutics, Inc. is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.

Explore Our Pipeline
Pipeline

Our pipeline

Arcutis has built a broad and deep dermatology pipeline.

Topical

Phosphodiesterase 4 (PDE4) inhibitor
Disease state Atopic dermatitis
Phase
  • P
  • 1
  • 2
  • 3
 Investigational therapy Roflumilast cream (ARQ-151)
Disease state Scalp and body psoriasis
Phase
  • P
  • 1
  • 2
  • 3
 Investigational therapy Roflumilast foam (ARQ-154)

Topical

Janus kinase 1 (JAK1) inhibitor
Disease state Alopecia areata
Phase
  • P
  • 1
  • 2
  • 3
 Investigational therapy JAK1 inhibitor suspension (ARQ-255)
Disease state Chronic hand eczema
Phase
  • P
  • 1
  • 2
  • 3
 Investigational therapy JAK1 inhibitor cream (ARQ-252)
Disease state Vitiligo
Phase
  • P
  • 1
  • 2
  • 3
 Investigational therapy JAK1 inhibitor cream (ARQ-252)

Biologic

CD200 receptor (CD200R) agonist
Disease state Atopic dermatitis
Phase
  • P
  • 1
  • 2
  • 3
 Investigational therapy CD200R agonist (ARQ-234)

P = preclinical

This website is intended for US healthcare professionals only. There may be information included that pertains to an investigational therapy or formulation that has not yet been approved for use in your country. The safety and efficacy of investigational therapies and/or formulations and/or uses have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. This information is as of 12/2023 to the best of the Company’s knowledge and Arcutis assumes no obligation to update this information.

© 2024 Arcutis Biotherapeutics, Inc. All rights reserved. MED-MULTI-2100006 v5.0 12/23